Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.5 USD | -5.18% |
|
-0.41% | -2.92% |
| Feb. 09 | UBS Adjusts DexCom Price Target to $153 From $149, Maintains Buy Rating | MT |
| Feb. 09 | This time it's for real |  |
Financials (USD)
| Sales 2024 * | 4.32B | Sales 2025 * | 5.15B | Capitalization | 46.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 672M | Net income 2025 * | 880M | EV / Sales 2024 * | 11.1 x |
| Net Debt 2024 * | 1.51B | Net Debt 2025 * | 911M | EV / Sales 2025 * | 9.2 x |
| P/E ratio 2024 * |
72.5
x | P/E ratio 2025 * |
56.6
x | Employees | 7,550 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
More news
| 1 day | -5.18% | ||
| 1 week | -0.41% | ||
| Current month | -0.73% | ||
| 1 month | -7.12% | ||
| 3 months | +30.38% | ||
| 6 months | +8.57% | ||
| Current year | -2.92% |
1 week
119.60
127.37
1 month
119.55130.31
Current year
119.55132.03
1 year
74.75139.55
3 years
66.89164.86
5 years
26.86164.86
10 years
7.02164.86
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 18-08-31 |
| Chief Tech/Sci/R&D Officer | 47 | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 14-11-18 |
Eric Topol
BRD | Director/Board Member | 69 | 09-07-08 |
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.46% | 19 M€ | +2.97% | - | |
| 1.04% | 17 M€ | -1.12% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 120.5 | -5.18% | 5,639,150 |
| 24-02-08 | 127 | +0.35% | 4,298,564 |
| 24-02-07 | 126.6 | +1.35% | 2,246,575 |
| 24-02-06 | 124.9 | +3.04% | 1,988,440 |
| 24-02-05 | 121.2 | +0.22% | 2,714,769 |
Delayed Quote Nasdaq, February 09, 2024 at 04:00 pm EST
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 73.6% of net sales.
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
120.5
USD
Average target price
145.6
USD
Spread / Average Target
+20.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.92% | 46 443 M $ | |
| +1.58% | 194 B $ | |
| +3.17% | 113 B $ | |
| +12.32% | 45 970 M $ | |
| +1.73% | 42 088 M $ | |
| +16.34% | 30 309 M $ | |
| +17.68% | 27 044 M $ | |
| +0.90% | 25 663 M $ | |
| -3.17% | 25 468 M $ | |
| +4.55% | 24 884 M $ |
